nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—Phenylephrine—Salbutamol—chronic obstructive pulmonary disease	0.369	1	CrCrCtD
Tapentadol—SLC6A4—chronic obstructive pulmonary disease	0.277	1	CbGaD
Tapentadol—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0315	0.145	CbGbCtD
Tapentadol—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0315	0.145	CbGbCtD
Tapentadol—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0262	0.12	CbGbCtD
Tapentadol—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0262	0.12	CbGbCtD
Tapentadol—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0239	0.11	CbGbCtD
Tapentadol—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0239	0.11	CbGbCtD
Tapentadol—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0213	0.098	CbGbCtD
Tapentadol—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0198	0.0912	CbGbCtD
Tapentadol—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0132	0.0608	CbGbCtD
Tapentadol—Phenylephrine—CYP1A2—chronic obstructive pulmonary disease	0.000561	1	CrCbGaD
Tapentadol—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000228	0.00235	CcSEcCtD
Tapentadol—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000227	0.00234	CcSEcCtD
Tapentadol—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.00233	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000224	0.00231	CcSEcCtD
Tapentadol—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00231	CcSEcCtD
Tapentadol—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00231	CcSEcCtD
Tapentadol—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000223	0.0023	CcSEcCtD
Tapentadol—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.0023	CcSEcCtD
Tapentadol—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000222	0.0023	CcSEcCtD
Tapentadol—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000222	0.00229	CcSEcCtD
Tapentadol—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000222	0.00229	CcSEcCtD
Tapentadol—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000221	0.00228	CcSEcCtD
Tapentadol—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000219	0.00226	CcSEcCtD
Tapentadol—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.00226	CcSEcCtD
Tapentadol—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000218	0.00225	CcSEcCtD
Tapentadol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000216	0.00223	CcSEcCtD
Tapentadol—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00222	CcSEcCtD
Tapentadol—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00222	CcSEcCtD
Tapentadol—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00222	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.00219	CcSEcCtD
Tapentadol—Cough—Formoterol—chronic obstructive pulmonary disease	0.000212	0.00219	CcSEcCtD
Tapentadol—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.00219	CcSEcCtD
Tapentadol—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00218	CcSEcCtD
Tapentadol—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00217	CcSEcCtD
Tapentadol—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00021	0.00217	CcSEcCtD
Tapentadol—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00021	0.00217	CcSEcCtD
Tapentadol—Cough—Montelukast—chronic obstructive pulmonary disease	0.000208	0.00215	CcSEcCtD
Tapentadol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000207	0.00214	CcSEcCtD
Tapentadol—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00214	CcSEcCtD
Tapentadol—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00214	CcSEcCtD
Tapentadol—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000206	0.00213	CcSEcCtD
Tapentadol—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000206	0.00213	CcSEcCtD
Tapentadol—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000206	0.00213	CcSEcCtD
Tapentadol—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00213	CcSEcCtD
Tapentadol—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00213	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000205	0.00212	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000205	0.00212	CcSEcCtD
Tapentadol—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00209	CcSEcCtD
Tapentadol—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000203	0.00209	CcSEcCtD
Tapentadol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000202	0.00209	CcSEcCtD
Tapentadol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000202	0.00209	CcSEcCtD
Tapentadol—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00209	CcSEcCtD
Tapentadol—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00208	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000201	0.00208	CcSEcCtD
Tapentadol—Cough—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00207	CcSEcCtD
Tapentadol—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.00205	CcSEcCtD
Tapentadol—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000198	0.00205	CcSEcCtD
Tapentadol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000198	0.00205	CcSEcCtD
Tapentadol—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000198	0.00205	CcSEcCtD
Tapentadol—Infection—Formoterol—chronic obstructive pulmonary disease	0.000197	0.00204	CcSEcCtD
Tapentadol—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.00204	CcSEcCtD
Tapentadol—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00202	CcSEcCtD
Tapentadol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000195	0.00202	CcSEcCtD
Tapentadol—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00201	CcSEcCtD
Tapentadol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000195	0.00201	CcSEcCtD
Tapentadol—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000195	0.00201	CcSEcCtD
Tapentadol—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000194	0.00201	CcSEcCtD
Tapentadol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000194	0.00201	CcSEcCtD
Tapentadol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000194	0.002	CcSEcCtD
Tapentadol—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.002	CcSEcCtD
Tapentadol—Infection—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00199	CcSEcCtD
Tapentadol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000193	0.00199	CcSEcCtD
Tapentadol—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000193	0.00199	CcSEcCtD
Tapentadol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000192	0.00198	CcSEcCtD
Tapentadol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00197	CcSEcCtD
Tapentadol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000191	0.00197	CcSEcCtD
Tapentadol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000189	0.00195	CcSEcCtD
Tapentadol—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000188	0.00194	CcSEcCtD
Tapentadol—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00193	CcSEcCtD
Tapentadol—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000187	0.00193	CcSEcCtD
Tapentadol—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00192	CcSEcCtD
Tapentadol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.00191	CcSEcCtD
Tapentadol—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000185	0.00191	CcSEcCtD
Tapentadol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000184	0.0019	CcSEcCtD
Tapentadol—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.0019	CcSEcCtD
Tapentadol—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.0019	CcSEcCtD
Tapentadol—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00189	CcSEcCtD
Tapentadol—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000182	0.00188	CcSEcCtD
Tapentadol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000181	0.00187	CcSEcCtD
Tapentadol—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00187	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00187	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00187	CcSEcCtD
Tapentadol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.00185	CcSEcCtD
Tapentadol—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000179	0.00185	CcSEcCtD
Tapentadol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000178	0.00184	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000177	0.00183	CcSEcCtD
Tapentadol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000177	0.00183	CcSEcCtD
Tapentadol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.00183	CcSEcCtD
Tapentadol—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.00182	CcSEcCtD
Tapentadol—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000176	0.00182	CcSEcCtD
Tapentadol—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000176	0.00182	CcSEcCtD
Tapentadol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00181	CcSEcCtD
Tapentadol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000175	0.0018	CcSEcCtD
Tapentadol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000175	0.0018	CcSEcCtD
Tapentadol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000174	0.0018	CcSEcCtD
Tapentadol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000174	0.0018	CcSEcCtD
Tapentadol—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000173	0.00178	CcSEcCtD
Tapentadol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000172	0.00178	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00177	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00177	CcSEcCtD
Tapentadol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000171	0.00177	CcSEcCtD
Tapentadol—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00177	CcSEcCtD
Tapentadol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00177	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00176	CcSEcCtD
Tapentadol—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00175	CcSEcCtD
Tapentadol—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00175	CcSEcCtD
Tapentadol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.00175	CcSEcCtD
Tapentadol—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000168	0.00174	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000168	0.00173	CcSEcCtD
Tapentadol—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00173	CcSEcCtD
Tapentadol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00172	CcSEcCtD
Tapentadol—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.00172	CcSEcCtD
Tapentadol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000166	0.00171	CcSEcCtD
Tapentadol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000165	0.0017	CcSEcCtD
Tapentadol—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000164	0.0017	CcSEcCtD
Tapentadol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000164	0.0017	CcSEcCtD
Tapentadol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000163	0.00169	CcSEcCtD
Tapentadol—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000163	0.00169	CcSEcCtD
Tapentadol—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000163	0.00169	CcSEcCtD
Tapentadol—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00168	CcSEcCtD
Tapentadol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00168	CcSEcCtD
Tapentadol—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000162	0.00167	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00167	CcSEcCtD
Tapentadol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00167	CcSEcCtD
Tapentadol—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00165	CcSEcCtD
Tapentadol—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00164	CcSEcCtD
Tapentadol—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000158	0.00163	CcSEcCtD
Tapentadol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000158	0.00163	CcSEcCtD
Tapentadol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000156	0.00161	CcSEcCtD
Tapentadol—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000155	0.0016	CcSEcCtD
Tapentadol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000155	0.0016	CcSEcCtD
Tapentadol—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000155	0.0016	CcSEcCtD
Tapentadol—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000154	0.00159	CcSEcCtD
Tapentadol—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000154	0.00159	CcSEcCtD
Tapentadol—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000154	0.00159	CcSEcCtD
Tapentadol—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000154	0.00159	CcSEcCtD
Tapentadol—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00157	CcSEcCtD
Tapentadol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00154	CcSEcCtD
Tapentadol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000146	0.00151	CcSEcCtD
Tapentadol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000146	0.00151	CcSEcCtD
Tapentadol—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000146	0.00151	CcSEcCtD
Tapentadol—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000146	0.00151	CcSEcCtD
Tapentadol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000143	0.00148	CcSEcCtD
Tapentadol—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000142	0.00147	CcSEcCtD
Tapentadol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000142	0.00147	CcSEcCtD
Tapentadol—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.00014	0.00145	CcSEcCtD
Tapentadol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.00014	0.00145	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.00014	0.00145	CcSEcCtD
Tapentadol—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000139	0.00144	CcSEcCtD
Tapentadol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000138	0.00143	CcSEcCtD
Tapentadol—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000137	0.00142	CcSEcCtD
Tapentadol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000136	0.0014	CcSEcCtD
Tapentadol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000136	0.0014	CcSEcCtD
Tapentadol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000134	0.00139	CcSEcCtD
Tapentadol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000133	0.00137	CcSEcCtD
Tapentadol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000133	0.00137	CcSEcCtD
Tapentadol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00135	CcSEcCtD
Tapentadol—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00135	CcSEcCtD
Tapentadol—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000128	0.00133	CcSEcCtD
Tapentadol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000128	0.00132	CcSEcCtD
Tapentadol—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000126	0.00131	CcSEcCtD
Tapentadol—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000126	0.0013	CcSEcCtD
Tapentadol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.0013	CcSEcCtD
Tapentadol—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.00129	CcSEcCtD
Tapentadol—Rash—Formoterol—chronic obstructive pulmonary disease	0.000125	0.00129	CcSEcCtD
Tapentadol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000125	0.00129	CcSEcCtD
Tapentadol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.00129	CcSEcCtD
Tapentadol—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000124	0.00128	CcSEcCtD
Tapentadol—Headache—Formoterol—chronic obstructive pulmonary disease	0.000124	0.00128	CcSEcCtD
Tapentadol—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000124	0.00128	CcSEcCtD
Tapentadol—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.00128	CcSEcCtD
Tapentadol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.00128	CcSEcCtD
Tapentadol—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000124	0.00128	CcSEcCtD
Tapentadol—Rash—Montelukast—chronic obstructive pulmonary disease	0.000122	0.00127	CcSEcCtD
Tapentadol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000122	0.00126	CcSEcCtD
Tapentadol—Depression—Prednisone—chronic obstructive pulmonary disease	0.000122	0.00126	CcSEcCtD
Tapentadol—Headache—Montelukast—chronic obstructive pulmonary disease	0.000122	0.00126	CcSEcCtD
Tapentadol—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.00012	0.00124	CcSEcCtD
Tapentadol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.00123	CcSEcCtD
Tapentadol—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00122	CcSEcCtD
Tapentadol—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.00122	CcSEcCtD
Tapentadol—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00122	CcSEcCtD
Tapentadol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.00122	CcSEcCtD
Tapentadol—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000118	0.00122	CcSEcCtD
Tapentadol—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000118	0.00122	CcSEcCtD
Tapentadol—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000117	0.00121	CcSEcCtD
Tapentadol—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.00119	CcSEcCtD
Tapentadol—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000115	0.00119	CcSEcCtD
Tapentadol—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000114	0.00118	CcSEcCtD
Tapentadol—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000112	0.00116	CcSEcCtD
Tapentadol—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000111	0.00115	CcSEcCtD
Tapentadol—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00113	CcSEcCtD
Tapentadol—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000108	0.00112	CcSEcCtD
Tapentadol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.00111	CcSEcCtD
Tapentadol—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.00111	CcSEcCtD
Tapentadol—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.00109	CcSEcCtD
Tapentadol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.00108	CcSEcCtD
Tapentadol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000104	0.00107	CcSEcCtD
Tapentadol—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000103	0.00106	CcSEcCtD
Tapentadol—Angiopathy—Prednisone—chronic obstructive pulmonary disease	9.97e-05	0.00103	CcSEcCtD
Tapentadol—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	9.92e-05	0.00103	CcSEcCtD
Tapentadol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	9.72e-05	0.001	CcSEcCtD
Tapentadol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	9.65e-05	0.000996	CcSEcCtD
Tapentadol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	9.63e-05	0.000994	CcSEcCtD
Tapentadol—Malnutrition—Prednisone—chronic obstructive pulmonary disease	9.56e-05	0.000988	CcSEcCtD
Tapentadol—Vision blurred—Prednisone—chronic obstructive pulmonary disease	9.01e-05	0.000931	CcSEcCtD
Tapentadol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	8.85e-05	0.000914	CcSEcCtD
Tapentadol—Agitation—Prednisone—chronic obstructive pulmonary disease	8.79e-05	0.000908	CcSEcCtD
Tapentadol—Angioedema—Prednisone—chronic obstructive pulmonary disease	8.74e-05	0.000903	CcSEcCtD
Tapentadol—Vertigo—Prednisone—chronic obstructive pulmonary disease	8.59e-05	0.000888	CcSEcCtD
Tapentadol—Syncope—Prednisone—chronic obstructive pulmonary disease	8.58e-05	0.000886	CcSEcCtD
Tapentadol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	8.53e-05	0.000881	CcSEcCtD
Tapentadol—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	8.41e-05	0.000868	CcSEcCtD
Tapentadol—Convulsion—Prednisone—chronic obstructive pulmonary disease	8.29e-05	0.000856	CcSEcCtD
Tapentadol—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.14e-05	0.000841	CcSEcCtD
Tapentadol—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.11e-05	0.000838	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.09e-05	0.000835	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	7.91e-05	0.000818	CcSEcCtD
Tapentadol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000806	CcSEcCtD
Tapentadol—Oedema—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000806	CcSEcCtD
Tapentadol—Infection—Prednisone—chronic obstructive pulmonary disease	7.75e-05	0.000801	CcSEcCtD
Tapentadol—Shock—Prednisone—chronic obstructive pulmonary disease	7.68e-05	0.000793	CcSEcCtD
Tapentadol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	7.65e-05	0.000791	CcSEcCtD
Tapentadol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.000787	CcSEcCtD
Tapentadol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	7.58e-05	0.000783	CcSEcCtD
Tapentadol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	7.55e-05	0.000779	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.11e-05	0.000735	CcSEcCtD
Tapentadol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.1e-05	0.000734	CcSEcCtD
Tapentadol—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.06e-05	0.000729	CcSEcCtD
Tapentadol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	7.01e-05	0.000724	CcSEcCtD
Tapentadol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	6.87e-05	0.00071	CcSEcCtD
Tapentadol—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	6.79e-05	0.000701	CcSEcCtD
Tapentadol—Rash—Prednisolone—chronic obstructive pulmonary disease	6.77e-05	0.0007	CcSEcCtD
Tapentadol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	6.77e-05	0.000699	CcSEcCtD
Tapentadol—Fatigue—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.000695	CcSEcCtD
Tapentadol—Headache—Prednisolone—chronic obstructive pulmonary disease	6.73e-05	0.000695	CcSEcCtD
Tapentadol—Constipation—Prednisone—chronic obstructive pulmonary disease	6.68e-05	0.00069	CcSEcCtD
Tapentadol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.43e-05	0.000664	CcSEcCtD
Tapentadol—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.38e-05	0.000659	CcSEcCtD
Tapentadol—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.2e-05	0.000641	CcSEcCtD
Tapentadol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	5.75e-05	0.000594	CcSEcCtD
Tapentadol—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.6e-05	0.000579	CcSEcCtD
Tapentadol—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.52e-05	0.00057	CcSEcCtD
Tapentadol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.34e-05	0.000552	CcSEcCtD
Tapentadol—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.16e-05	0.000533	CcSEcCtD
Tapentadol—Vomiting—Prednisone—chronic obstructive pulmonary disease	4.96e-05	0.000513	CcSEcCtD
Tapentadol—Rash—Prednisone—chronic obstructive pulmonary disease	4.92e-05	0.000508	CcSEcCtD
Tapentadol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	4.92e-05	0.000508	CcSEcCtD
Tapentadol—Headache—Prednisone—chronic obstructive pulmonary disease	4.89e-05	0.000505	CcSEcCtD
Tapentadol—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	4.8e-05	0.00122	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	4.78e-05	0.00122	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	4.77e-05	0.00121	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	4.74e-05	0.00121	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.72e-05	0.0012	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.68e-05	0.00119	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.66e-05	0.00119	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—TGFB1—chronic obstructive pulmonary disease	4.65e-05	0.00118	CbGpPWpGaD
Tapentadol—Nausea—Prednisone—chronic obstructive pulmonary disease	4.64e-05	0.000479	CcSEcCtD
Tapentadol—OPRD1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	4.63e-05	0.00118	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.62e-05	0.00118	CbGpPWpGaD
Tapentadol—HTR3A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.48e-05	0.00114	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.41e-05	0.00112	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.41e-05	0.00112	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.38e-05	0.00111	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.36e-05	0.00111	CbGpPWpGaD
Tapentadol—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	4.35e-05	0.00111	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.32e-05	0.0011	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.29e-05	0.00109	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.26e-05	0.00109	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.26e-05	0.00108	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.2e-05	0.00107	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GC—chronic obstructive pulmonary disease	4.2e-05	0.00107	CbGpPWpGaD
Tapentadol—OPRK1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	4.06e-05	0.00103	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	4.06e-05	0.00103	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	4.04e-05	0.00103	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.01e-05	0.00102	CbGpPWpGaD
Tapentadol—UGT2B7—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.97e-05	0.00101	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.92e-05	0.000998	CbGpPWpGaD
Tapentadol—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.91e-05	0.000996	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.91e-05	0.000995	CbGpPWpGaD
Tapentadol—OPRD1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.91e-05	0.000995	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.89e-05	0.00099	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.87e-05	0.000987	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.87e-05	0.000985	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.87e-05	0.000985	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.84e-05	0.000977	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.83e-05	0.000976	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.83e-05	0.000975	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.78e-05	0.000962	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	3.73e-05	0.000949	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.68e-05	0.000938	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.63e-05	0.000924	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.6e-05	0.000918	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.55e-05	0.000905	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.51e-05	0.000895	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.51e-05	0.000894	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.51e-05	0.000893	CbGpPWpGaD
Tapentadol—OPRM1—TCR Signaling Pathway—IL6—chronic obstructive pulmonary disease	3.5e-05	0.000892	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.48e-05	0.000887	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.47e-05	0.000882	CbGpPWpGaD
Tapentadol—OPRM1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	3.43e-05	0.000874	CbGpPWpGaD
Tapentadol—OPRK1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.43e-05	0.000872	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GC—chronic obstructive pulmonary disease	3.42e-05	0.00087	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.4e-05	0.000865	CbGpPWpGaD
Tapentadol—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.36e-05	0.000857	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.36e-05	0.000855	CbGpPWpGaD
Tapentadol—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.35e-05	0.000854	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.29e-05	0.000837	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.27e-05	0.000833	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.27e-05	0.000833	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.27e-05	0.000832	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.24e-05	0.000826	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.24e-05	0.000825	CbGpPWpGaD
Tapentadol—UGT1A9—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.23e-05	0.000822	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.22e-05	0.000821	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.22e-05	0.00082	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.2e-05	0.000814	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.18e-05	0.000809	CbGpPWpGaD
Tapentadol—HTR3A—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.17e-05	0.000808	CbGpPWpGaD
Tapentadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.11e-05	0.000791	CbGpPWpGaD
Tapentadol—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.1e-05	0.000789	CbGpPWpGaD
Tapentadol—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.05e-05	0.000778	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3e-05	0.000765	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.98e-05	0.000758	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.97e-05	0.000756	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.96e-05	0.000755	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.94e-05	0.000748	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.94e-05	0.000748	CbGpPWpGaD
Tapentadol—OPRM1—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	2.9e-05	0.000737	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.87e-05	0.000731	CbGpPWpGaD
Tapentadol—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.85e-05	0.000725	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.84e-05	0.000723	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.84e-05	0.000723	CbGpPWpGaD
Tapentadol—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.82e-05	0.000719	CbGpPWpGaD
Tapentadol—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.81e-05	0.000715	CbGpPWpGaD
Tapentadol—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.8e-05	0.000712	CbGpPWpGaD
Tapentadol—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.78e-05	0.000709	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.77e-05	0.000705	CbGpPWpGaD
Tapentadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.72e-05	0.000694	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.57e-05	0.000656	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.53e-05	0.000644	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.51e-05	0.00064	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.49e-05	0.000635	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	2.49e-05	0.000634	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.47e-05	0.00063	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.43e-05	0.000618	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.37e-05	0.000603	CbGpPWpGaD
Tapentadol—OPRD1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.37e-05	0.000602	CbGpPWpGaD
Tapentadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.3e-05	0.000586	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.3e-05	0.000585	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.29e-05	0.000584	CbGpPWpGaD
Tapentadol—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.28e-05	0.000581	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.27e-05	0.000578	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GCLC—chronic obstructive pulmonary disease	2.27e-05	0.000578	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.25e-05	0.000572	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.2e-05	0.000561	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.18e-05	0.000554	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.17e-05	0.000552	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.16e-05	0.000551	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.08e-05	0.000528	CbGpPWpGaD
Tapentadol—OPRK1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.07e-05	0.000528	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CTGF—chronic obstructive pulmonary disease	2.07e-05	0.000527	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.05e-05	0.000522	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.97e-05	0.000501	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.96e-05	0.0005	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.91e-05	0.000486	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.9e-05	0.000483	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.87e-05	0.000475	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.86e-05	0.000474	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.84e-05	0.00047	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.83e-05	0.000467	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.78e-05	0.000452	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.75e-05	0.000447	CbGpPWpGaD
Tapentadol—OPRM1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.75e-05	0.000446	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.73e-05	0.000441	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.72e-05	0.000439	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.72e-05	0.000438	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.7e-05	0.000434	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.68e-05	0.000429	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.66e-05	0.000424	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.65e-05	0.00042	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.64e-05	0.000417	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.62e-05	0.000412	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.61e-05	0.00041	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.61e-05	0.000409	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.6e-05	0.000408	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.59e-05	0.000405	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.57e-05	0.0004	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.55e-05	0.000395	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.52e-05	0.000387	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.52e-05	0.000386	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.5e-05	0.000383	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.49e-05	0.00038	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.49e-05	0.00038	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.48e-05	0.000378	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.48e-05	0.000376	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.46e-05	0.000373	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.46e-05	0.000372	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.46e-05	0.000371	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.41e-05	0.000359	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.39e-05	0.000353	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.37e-05	0.00035	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.36e-05	0.000347	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.34e-05	0.00034	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.33e-05	0.000338	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.3e-05	0.000332	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.29e-05	0.000329	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.28e-05	0.000327	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.28e-05	0.000325	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.21e-05	0.000309	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.21e-05	0.000307	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.19e-05	0.000304	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.19e-05	0.000303	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.19e-05	0.000303	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.17e-05	0.000298	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.16e-05	0.000296	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.16e-05	0.000296	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.13e-05	0.000287	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.1e-05	0.00028	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.08e-05	0.000276	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.08e-05	0.000275	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.06e-05	0.000271	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.06e-05	0.000269	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.02e-05	0.000259	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.91e-06	0.000252	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.83e-06	0.00025	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.46e-06	0.000241	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—chronic obstructive pulmonary disease	9.43e-06	0.00024	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NOS3—chronic obstructive pulmonary disease	9.02e-06	0.00023	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9e-06	0.000229	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.94e-06	0.000228	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	8.87e-06	0.000226	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.77e-06	0.000223	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	8.67e-06	0.000221	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.6e-06	0.000219	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.47e-06	0.000216	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.08e-06	0.000206	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	8.08e-06	0.000206	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.07e-06	0.000205	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	8e-06	0.000204	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8e-06	0.000204	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.97e-06	0.000203	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	7.91e-06	0.000201	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.91e-06	0.000201	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.78e-06	0.000198	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—chronic obstructive pulmonary disease	7.66e-06	0.000195	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.42e-06	0.000189	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.37e-06	0.000188	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NOS3—chronic obstructive pulmonary disease	7.33e-06	0.000187	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.29e-06	0.000186	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	7.28e-06	0.000185	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	7.21e-06	0.000184	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.17e-06	0.000183	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.09e-06	0.000181	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.82e-06	0.000174	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.7e-06	0.000171	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.65e-06	0.000169	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.58e-06	0.000167	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.49e-06	0.000165	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.29e-06	0.00016	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.27e-06	0.00016	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.08e-06	0.000155	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	6e-06	0.000153	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.99e-06	0.000153	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.98e-06	0.000152	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.82e-06	0.000148	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.69e-06	0.000145	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.59e-06	0.000142	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.59e-06	0.000142	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.54e-06	0.000141	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.51e-06	0.00014	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.47e-06	0.000139	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.35e-06	0.000136	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.31e-06	0.000135	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.3e-06	0.000135	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.24e-06	0.000133	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.14e-06	0.000131	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.11e-06	0.00013	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.09e-06	0.00013	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.05e-06	0.000129	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.87e-06	0.000124	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.83e-06	0.000123	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.81e-06	0.000122	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.69e-06	0.000119	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.6e-06	0.000117	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.4e-06	0.000112	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.32e-06	0.00011	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.03e-06	0.000103	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.96e-06	0.000101	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.88e-06	9.89e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.86e-06	9.83e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.6e-06	9.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.53e-06	8.99e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	3.44e-06	8.77e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.31e-06	8.43e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.28e-06	8.36e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.26e-06	8.3e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.17e-06	8.07e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.14e-06	8e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.99e-06	7.6e-05	CbGpPWpGaD
